TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries is presenting new data at the 2025 International Society for Extracellular Vesicles (ISEV) Annual Meeting being held in Vienna April 24-27.
The ISEV presentation will feature facial nerve regeneration, marking the Company’s third therapeutic indication, alongside its ongoing programs in spinal cord injury and optic nerve regeneration. In a preclinical model of facial nerve injury, NurExone’s lead candidate, ExoPTEN was shown to promote significant functional recovery and regeneration. These findings open, for the first time, a new potential therapeutic avenue for peripheral nerve injury conditions such as Bell’s palsy, Ramsay Hunt Syndrome (Herpes Zoster Oticus), and other infections that damage the facial nerve. Approximately 30% of patients affected by these conditions experience long-term functional impairment, including facial asymmetry, synkinesis, chronic tearing, and difficulties with eating or speaking 1. This new indication may allow NurExone to enter a third multi-billion dollar addressable market2.